Expert Profile

Share QR code Edit Profile

Robert Hauser

Medical Director

USF PARKINSON'S DISEASE AND MOVEMENT DISORDERS | MORSANI COLLEGE OF MEDICINE

View:

Select
All (all in one) Research Terms and Keywords Background Publications Speaker Information Center Network Websites Contact

All
Research
Background
Publications
Speaker
Center
Network
Websites
Contact

Research Terms & Keywords

Research Terms

Neurology

Research Projects

Ends

Title

05-2029

A Randomized, Double-Blind, Placebo-Controlled Trial of A Randomized, Double-Blind, Placebo-Controlled Trial of

Cerevance Beta, Inc.

11-2028

A Global Real-World Evidence Study on the Long-term Effe A Global Real-World Evidence Study on the Long-term Effe

AbbVie Inc.

06-2028

IkT-148009-201/ A Phase 2, Randomized, Double-Blind, Pla IkT-148009-201/ A Phase 2, Randomized, Double-Blind, Pla

Inhibikase Therapeutics, Inc.

06-2028

A Multicenter, Single-Dose, Multiple-Dose, Randomized, A Multicenter, Single-Dose, Multiple-Dose, Randomized,

Enterin, Inc.

04-2028

A Randomized, Double-blind, Placebo-controlled Study to A Randomized, Double-blind, Placebo-controlled Study to

Sage Therapeutics, Inc.

03-2028

A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM

UCB BIOPHARMA SRL

02-2028

A 17-week, Phase 2, Randomized, Double-blind, Placebo-co A 17-week, Phase 2, Randomized, Double-blind, Placebo-co

Cavion, Inc.

12-2027

A 6-month prospective, randomized, double-blind, placebo A 6-month prospective, randomized, double-blind, placebo

Annovis Bio, Inc.

04-2027

A Phase 2b, 12-week, Double-blind, Placebo-controlled, R A Phase 2b, 12-week, Double-blind, Placebo-controlled, R

Cavion, Inc.

06-2026

A Phase 3, Multicenter, Randomized, Double-Blind, Placeb A Phase 3, Multicenter, Randomized, Double-Blind, Placeb

Biogen MA

04-2026

58 Week Open-Label Trial of Tavapadon in Parkinson¿s Dis 58 Week Open-Label Trial of Tavapadon in Parkinson¿s Dis

Cerevel Therapeutics, LLC

03-2026

A Randomized, Double-Blind, Placebo-Controlled, Phase II A Randomized, Double-Blind, Placebo-Controlled, Phase II

Integrative Research Laboratories Sweden

02-2026

A Phase 2b, Multicenter, Randomized, Double-Blind, Place A Phase 2b, Multicenter, Randomized, Double-Blind, Place

Biogen MA

02-2026

¿A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONT ¿A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONT

UCB BIOPHARMA SRL

11-2025

An Open-Label Extension Of Study M15-736 To Evaluate The An Open-Label Extension Of Study M15-736 To Evaluate The

AbbVie Inc.

04-2025

Protocol #CVN424-201 Protocol #CVN424-201

Cerevance Beta, Inc.

04-2025

Protocol #M15-736 Protocol #M15-736

AbbVie Inc.

03-2025

Protocol #ND0612-317 Protocol #ND0612-317

NeuroDerm Ltd.

03-2025

Protocol #CVL-751-PD-001 Protocol #CVL-751-PD-001

Cerevel Therapeutics, LLC

02-2025

Protocol #NLY01-PD-1 Protocol #NLY01-PD-1

Neuraly Inc.

11-2024

Protocol #Study 003 Protocol #Study 003

Global Kinetics Corporation

10-2024

Protocol #POOP-9009 Protocol #POOP-9009

Enterin, Inc.

05-2024

Non-Invasive Brainstem Modulation for the Treatment of N Non-Invasive Brainstem Modulation for the Treatment of N

Scion NeuroStim, LLC

04-2024

A Phase 2, Randomized, Double-Blind, Multicenter, Placeb A Phase 2, Randomized, Double-Blind, Multicenter, Placeb

Aeon Biopharma, Inc.

04-2024

An Open-Label, Multicenter Study to Evaluate the Safety An Open-Label, Multicenter Study to Evaluate the Safety

Aeon Biopharma, Inc.

03-2024

Protocol #Study 002 Protocol #Study 002

Global Kinetics Corporation

02-2024

Protocol #IPX203-B16-02 Protocol #IPX203-B16-02

Impax Laboratories, Inc.

01-2024

Protocol #ROPAD 01-2019 Protocol #ROPAD 01-2019

Centogene AG

12-2023

OPTI-ON: Opicapone Treatment Initiation Open-Label Study OPTI-ON: Opicapone Treatment Initiation Open-Label Study

Neurocrine Biosciences, Inc

12-2023

Protocol #ENT-01-030 Protocol #ENT-01-030

Enterin, Inc.

10-2023

Protocol #CX-8998-CLN2-001 Protocol #CX-8998-CLN2-001

Cavion, Inc.

09-2023

A Randomized, Double-Blind, Placebo-Controlled, Two-Part A Randomized, Double-Blind, Placebo-Controlled, Two-Part

Bukwang Pharmaceutical Co., Ltd.

06-2023

Protocol: 002 Protocol: 002

Fox (Michael J.) Foundation for Parkinson's Research

04-2023

Protocol #OBS16136 Protocol #OBS16136

Sanofi Pharmaceuticals, Inc.

04-2023

Protocol #CVL-751-PD-003 Protocol #CVL-751-PD-003

Cerevel Therapeutics, LLC

02-2023

Protocol #P2B001/003 Protocol #P2B001/003

Pharma Two B Ltd.

01-2023

A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE

Genentech, Inc.

11-2022

Protocol #M19-304 Protocol #M19-304

AbbVie Inc.

11-2022

Protocol #NiloPD Protocol #NiloPD

Northwestern University

10-2022

Protocol #B7601017 Protocol #B7601017

Pfizer, Inc.

10-2022

Protocol #228PD201 Protocol #228PD201

Biogen, Inc.

09-2022

Protocol #DNS-7801-201 Protocol #DNS-7801-201

Dart NeuroScience, LLC

07-2022

Protocol #BP39529 Protocol #BP39529

Hoffmann-La Roche Inc.

05-2022

Protocol #ENT-01-1b-19-01 Protocol #ENT-01-1b-19-01

Enterin, Inc.

05-2022

Protocol #ENT-01 Protocol #ENT-01

Enterin, Inc.

04-2022

Protocol #IPX203-B16-03 Protocol #IPX203-B16-03

Impax Laboratories, Inc.

03-2022

Protocol #RVT-102-2002 Protocol #RVT-102-2002

Axovant Sciences, Inc

03-2022

Proposal #JZP166-201 Proposal #JZP166-201

Jazz Pharmaceuticals, Inc.

02-2022

Protocol #SEP361-2030 Protocol #SEP361-2030

Sunovion Pharmaceuticals

01-2022

Protocol #IPX203-B16-01 Protocol #IPX203-B16-01

Impax Laboratories, Inc.

11-2021

Protocol #CLR_18_06 Protocol #CLR_18_06

SunPharma

10-2021

Protocol #B7601011 Protocol #B7601011

Pfizer, Inc.

07-2021

Protocol #CVT-301-009 Protocol #CVT-301-009

Civitas Therapeutics

06-2021

Protocol #B7601003 Protocol #B7601003

Pfizer, Inc.

05-2021

Protocol #6002-018 Protocol #6002-018

Kyowa Pharmaceutical, Inc.

03-2021

Protocol #1720302 Protocol #1720302

Revance Therapeutic, Inc.

03-2021

Protocol #1720304 Protocol #1720304

Revance Therapeutic, Inc.

03-2021

Protocol #IN 11 04 Protocol #IN 11 04

Intec Pharma Ltd

01-2021

Protocol #IPX203-B14-02 Protocol #IPX203-B14-02

Impax Laboratories, Inc.

11-2020

Protocol #RT002-CL005 Protocol #RT002-CL005

Revance Therapeutic, Inc.

10-2020

Protocol #CTH-301 Protocol #CTH-301

CYNAPSUS Therapeutics Inc

07-2020

Protocol #iPX066-B09-03 Protocol #iPX066-B09-03

Impax Laboratories, Inc.

06-2020

Protocol #IPX066-B09-06 Protocol #IPX066-B09-06

Impax Laboratories, Inc.

05-2020

Protocol #RVT-102-2003 Protocol #RVT-102-2003

Axovant Sciences, Inc

04-2020

Protocol #TOZ-CL06 Protocol #TOZ-CL06

Biotie Therapies

03-2020

Protocol #D0490C00023 Protocol #D0490C00023

AstraZeneca Ltd.

03-2020

Protocol #Y-47-52844-003 Protocol #Y-47-52844-003

INC Research, Inc.

02-2020

Protocol #PILLAR III Protocol #PILLAR III

Novadaq Technologies Inc.

01-2020

Protocol #ND0612H-012 Protocol #ND0612H-012

NeuroDerm Ltd.

12-2019

Protocol #ND0612L-007 Protocol #ND0612L-007

INC Research, Inc.

12-2019

Protocol #CVT-301-004 Protocol #CVT-301-004

Civitas Therapeutics

12-2019

Protocol #CVT-301-004E Protocol #CVT-301-004E

Civitas Therapeutics

02-2019

Protocol #IN 11 004 OLE Protocol #IN 11 004 OLE

Intec Pharma Ltd

11-2018

Protocol #NOH402 Protocol #NOH402

H. Lundbeck A/S

07-2018

Protocol #PXT-CL17-003 Protocol #PXT-CL17-003

Prexton Therapeutics

06-2018

Protocol #CTH-300 Protocol #CTH-300

CYNAPSUS Therapeutics Inc

06-2018

Protocol #TOZ-CL05 Protocol #TOZ-CL05

Biotie Therapies

05-2018

A Phase 3 double-blind placebo-controlled parallel group study of isradipine CR as a disease modifying agent in subjects with early Parkinson disease A Phase 3 double-blind placebo-controlled parallel group study of isradipine CR as a disease modifying agent in subjects with early Parkinson disease

University of Rochester

12-2017

The Parkinson's Progression Markers Initiative (PP The Parkinson's Progression Markers Initiative (PP

Fox (Michael J.) Foundation for Parkinson's Research

11-2017

Protocol # ADS-AMT-PD301 Protocol # ADS-AMT-PD301

Adamas Pharmaceuticals, Inc

11-2017

Protocol #ADS-AMT-PD302 Protocol #ADS-AMT-PD302

Adamas Pharmaceuticals, Inc

10-2017

Protocol #CTH-105 Protocol #CTH-105

CYNAPSUS Therapeutics Inc

06-2017

A Randomized, Double-Blind, Placebo-Controlled Trial of A Randomized, Double-Blind, Placebo-Controlled Trial of

Brigham & Women's Hospital, Inc.

04-2017

Protocol #P2B001/001 Protocol #P2B001/001

Pharmaceutical Research Associates, Inc.

04-2017

Protocol # NOH401 Protocol # NOH401

Chelsea Therapeutics, Inc.

03-2017

Protocol #6002-014 Protocol #6002-014

Kyowa Pharmaceutical, Inc.

12-2016

Detecting medication Side Effects Using Anomaly Patterns Detecting medication Side Effects Using Anomaly Patterns

HealthAxis Group, LLC

12-2016

Community Grant Award for Parkinson's Disease 2016 Community Grant Award for Parkinson's Disease 2016

National Parkinson Foundation, Inc.

11-2016

Protocol # TVP-1012/PM106 Protocol # TVP-1012/PM106

TEVA Pharmaceutical USA

08-2016

Protocol #CVT-301-003 Protocol #CVT-301-003

Civitas Therapeutics

06-2016

Protocol #Top dysk Protocol #Top dysk

Fox (Michael J.) Foundation for Parkinson's Research

04-2016

Protocol #AFQ056A2216 Protocol #AFQ056A2216

Novartis Pharmaceutical Corporation

04-2016

Protocol #A-TL-52120-170 Protocol #A-TL-52120-170

Ipsen Limited

03-2016

Protocol# S187.3.005 Protocol# S187.3.005

AbbVie Inc.

03-2016

Protocol# A-TL-52120-169 Protocol# A-TL-52120-169

Ipsen Limited

01-2016

Protocol# D0490C00005 Protocol# D0490C00005

AstraZeneca Ltd.

01-2016

Protocol#NAI113678 Protocol#NAI113678

GlaxoSmithKline

11-2015

Protocol #AFQ056A2299 Protocol #AFQ056A2299

Novartis Pharmaceutical Corporation

11-2015

Protocol #V4.12 04.07.10 Protocol #V4.12 04.07.10

Pico-Tesla Magnetic Therapies, LLC

11-2015

Protocol# PD0005 Protocol# PD0005

UCB Biosciences, Inc

09-2015

Protocol # 196 Protocol # 196

Skye Pharma, Inc.

09-2015

Protocol #305405 Protocol #305405

Berlex Laboratories, Inc.

08-2015

Protocol #27918 Motion Protocol #27918 Motion

EMD Serono, Inc

08-2015

Protocol #27919 Protocol #27919

EMD Serono, Inc

07-2015

Protocol#MUS 60201 4073 1 Protocol#MUS 60201 4073 1

Merz Pharmaceuticals, LLC

07-2015

Protocol#AFQ056A2223 Protocol#AFQ056A2223

Novartis Pharmaceutical Corporation

06-2015

Protocol#NOH306 Protocol#NOH306

PPD Development, LP

06-2015

Protocol#TVP1012-PM103 Protocol#TVP1012-PM103

Premier Research Intl, LLC

05-2015

A Longitudinal Observational Follow-Up of the PREC A Longitudinal Observational Follow-Up of the PREC

University of Rochester

03-2015

Protocol #187.3.005 Protocol #187.3.005

Quintiles, Inc.

02-2015

Protocol#A-TL-52120-156 Protocol#A-TL-52120-156

Tercica, Inc

02-2015

Protocol #NP031112-08B02 Protocol #NP031112-08B02

i3 Research

11-2014

Protocol #IPX066-B09-02 Protocol #IPX066-B09-02

Pharmaceutical Research Associates, Inc

11-2014

Protocol # S187.3.003 Protocol # S187.3.003

Quintiles, Inc.

10-2014

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Trial to Assess the Disease-Modifying Potential of Transdermal Nicotine in Early Parkinson's Disease (NIC-PD) A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Trial to Assess the Disease-Modifying Potential of Transdermal Nicotine in Early Parkinson's Disease (NIC-PD)

University of Rochester

10-2014

Protocol# P06153 Protocol# P06153

Schering-Plough Corporation

09-2014

Protocol#TVP 1012/501 Protocol#TVP 1012/501

Teva Neuroscience, Inc.

09-2014

Protocol #TVP 1012/501 Protocol #TVP 1012/501

Teva Neuroscience, Inc.

09-2014

Protocol #28850 Protocol #28850

EMD Serono, Inc

09-2014

Protocol#IPX066-B11-01 Protocol#IPX066-B11-01

Impax Laboratories, Inc.

07-2014

Protocol #XP-C-069 Protocol #XP-C-069

XenoPort, Inc.

07-2014

Protocol#ADX48621-201 Protocol#ADX48621-201

Addex Pharmaceuticals SA

07-2014

Protocol#ADS-PAR-AM201 Protocol#ADS-PAR-AM201

Adamas Pharmaceuticals, Inc

05-2014

Protocol#SYN115-CL02 Protocol#SYN115-CL02

Biotie Therapies

04-2014

Protocol # EMR 701165-024 Protocol # EMR 701165-024

EMD Serono, Inc

04-2014

Protocol #IPX066-B08-05 Protocol #IPX066-B08-05

Pharmaceutical Research Associates, Inc

02-2014

Protocol#ACP-103-015 Protocol#ACP-103-015

Acadia Pharmaceuticals, Inc.

02-2014

Protocol #IPX066-B08-11 Protocol #IPX066-B08-11

Impax Laboratories, Inc.

01-2014

Protocol #DROXIDOPA-303 Protocol #DROXIDOPA-303

Chiltern International, Inc.

12-2013

Protocol #P05175-30 Protocol #P05175-30

Schering-Plough Corporation

11-2013

Parkinson's Disease Neuroprotection Clinical Trial Parkinson's Disease Neuroprotection Clinical Trial

National Institute of Neurological Disorders and Stroke

11-2013

Protocol # S187.3.001 Protocol # S187.3.001

Quintiles, Inc.

10-2013

Protocol #DROXIDOPA-302 Protocol #DROXIDOPA-302

Chiltern International, Inc.

05-2013

Protocol#S187.3.004 Protocol#S187.3.004

Quintiles, Inc.

05-2013

Protocol #S187.3.004 Protocol #S187.3.004

Quintiles, Inc.

03-2013

Evaluation of Blood Biospectroscopy as a Novel Diagnostic Test for Idiopathic Parkinson Disease (PD Biospec) Evaluation of Blood Biospectroscopy as a Novel Diagnostic Test for Idiopathic Parkinson Disease (PD Biospec)

University of Rochester

01-2013

Protocol #SNT-II-004 Protocol #SNT-II-004

i3 Research

12-2012

Protocol #PO4501 Protocol #PO4501

Schering-Plough Corporation

10-2012

Protocol#ACP-103-020 Protocol#ACP-103-020

PharmaNet, Inc.

10-2012

Protocol #ACP-103-020 Protocol #ACP-103-020

PharmaNet, Inc.

10-2012

Protocol #MSA-RAS-202 Protocol #MSA-RAS-202

TEVA Pharmaceutical USA

09-2012

Protocol #27938 Protocol #27938

EMD Serono, Inc

09-2012

Protocol #NOH306 Protocol #NOH306

PPD Development, LP

08-2012

Protocol #APO-4PD-01 Protocol #APO-4PD-01

Ipsen Limited

08-2012

Protocol #APO-4PD-01 Protocol #APO-4PD-01

Vernalis plc

07-2012

An Oligo-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rifampicin in Patients with Multiple System Atrophy An Oligo-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rifampicin in Patients with Multiple System Atrophy

Vanderbilt University

07-2012

Protocol #ASBI-501 Protocol #ASBI-501

Asubio Pharmaceuticals, Inc.

06-2012

A Randomized Recruitment Intervention A Randomized Recruitment Intervention

University of Texas

06-2012

Protocol #NCPD-003-99 Protocol #NCPD-003-99

Diacrin/Genzyme, LLC

05-2012

Protocol #S308.3.002 Protocol #S308.3.002

Quintiles, Inc.

05-2012

Protocol #S308.3.007 Protocol #S308.3.007

Quintiles, Inc.

04-2012

Protocol #E2007-G000-303 Protocol #E2007-G000-303

Eisai America, Inc.

03-2012

Protocol #PDT409 Protocol #PDT409

GE Healthcare

03-2012

Protocol #P58/07CL/ST/09/02 Protocol #P58/07CL/ST/09/02

ICON Clinical Research

02-2012

Protocol #3PT-ST-01 Protocol #3PT-ST-01

Mentor Corporation

02-2012

Protocol #P04938-2005 Protocol #P04938-2005

Schering-Plough Corporation

02-2012

Protocol #P05664-1007 Protocol #P05664-1007

Schering-Plough Corporation

11-2011

Protocol #0408 Protocol #0408

INC Research, Inc.

11-2011

Protocol #MRZ60201-0433 Protocol #MRZ60201-0433

INC Research, Inc.

10-2011

Protocol #E2007-A001-302 Protocol #E2007-A001-302

Eisai Company, Ltd.

10-2011

Validation of Dyskinesia Rating Scales - MJFF CTA Validation of Dyskinesia Rating Scales - MJFF CTA

Fox (Michael J.) Foundation for Parkinson's Research

08-2011

Protocol #308.3.001 Protocol #308.3.001

Quintiles, Inc.

06-2011

University of South Florida Parkinson's Disease an University of South Florida Parkinson's Disease an

National Parkinson Foundation, Inc.

03-2011

National Parkinson Foundation Patient Registry Pha National Parkinson Foundation Patient Registry Pha

National Parkinson Foundation, Inc.

02-2011

Protocol #191622-090 Protocol #191622-090

Allergan, Inc.

02-2011

Protocol #ACP-103-015 Protocol #ACP-103-015

Acadia Pharmaceuticals, Inc.

02-2011

CD Probe CD Probe

Allergan, Inc.

12-2010

Protocol #TR-2002 Protocol #TR-2002

GE Healthcare

11-2010

Parkinson's Disease (PD) Neutroprotection Clinical Trial Parkinson's Disease (PD) Neutroprotection Clinical Trial

National Institute of Neurological Disorders and Stroke

11-2010

Protocol #TVP 1012/500 Protocol #TVP 1012/500

Teva Neuroscience, Inc.

10-2010

Protocol #TVP1012-PM103 Protocol #TVP1012-PM103

Premier Research Intl, LLC

09-2010

Kyowa Pharmaceuticals/Protocol KW 6002-US-201 Kyowa Pharmaceuticals/Protocol KW 6002-US-201

Kyowa Pharmaceutical, Inc.

07-2010

Protocol #6002-US-051 Protocol #6002-US-051

Kyowa Pharmaceutical, Inc.

07-2010

Protocol #ACP-103-012 Protocol #ACP-103-012

INC Research, Inc.

06-2010

NPF Care Centers of Florida NPF Care Centers of Florida

National Parkinson Foundation, Inc.

06-2010

Support of Parkinson's Study Group Research and Tr Support of Parkinson's Study Group Research and Tr

University of Rochester

06-2010

NPF Care Centers of Florida PGI Account NPF Care Centers of Florida PGI Account

National Parkinson Foundation, Inc.

12-2009

TVP-1012/233 TVP-1012/233

Teva Pharmaceutical Ind., Ltd.

11-2009

Parkinson's Disease (PD) Neuroprotection Clinical Trial: Clinical Centers Parkinson's Disease (PD) Neuroprotection Clinical Trial: Clinical Centers

National Institute of Neurological Disorders and Stroke

10-2009

Protocol #PO 414475-G Protocol #PO 414475-G

University of Rochester

09-2009

KEPPRA KEPPRA

UCB Pharma, Inc.

09-2009

CL-758007 CL-758007

Neurochem, Inc.

06-2009

NPF Care Centers of Florida NPF Care Centers of Florida

National Parkinson Foundation, Inc.

02-2009

Protocol # 6002-US-025 Protocol # 6002-US-025

Kyowa Pharmaceutical, Inc.

02-2009

GlaxoSmithKline - Protocol #SK&F101468/248 GlaxoSmithKline - Protocol #SK&F101468/248

GlaxoSmithKline

12-2008

Protocol #OV-1005 Protocol #OV-1005

Kendle

12-2008

Protocol #OV-1005 Protocol #OV-1005

Ovation Pharmaceuticals, Inc.

11-2008

Parkinson's Disease (PD) Neuroprotection Clinical Trial: Clinical Centers Parkinson's Disease (PD) Neuroprotection Clinical Trial: Clinical Centers

National Institute of Neurological Disorders and Stroke

11-2008

Effects of Coenzyme Q10 in Parkinson's Disease-Phase 3 (QE3) Effects of Coenzyme Q10 in Parkinson's Disease-Phase 3 (QE3)

Cornell University

11-2008

PROBE PROBE

University of Rochester

10-2008

Wellness Health & Pharmacy/Protocol GSH Wellness Health & Pharmacy/Protocol GSH

Wellness Health & Pharmacy

10-2008

Protocol #248.595 Protocol #248.595

Boehringer Ingelheim Pharm., Inc.

07-2008

Protocol #1198.100 Protocol #1198.100

Boehringer Ingelheim Pharm., Inc.

07-2008

Protocol #666E-CNS-0618-007 Protocol #666E-CNS-0618-007

Pharmacia & Upjohn

06-2008

PARS-Parkinson's Associated Risk Study PARS-Parkinson's Associated Risk Study

Department of Defense

06-2008

PARS-Parkinson's Associated Risk Study PARS-Parkinson's Associated Risk Study

Inst. for Neurodegenerative Disorders

05-2008

Defining PD Subtypes Based on Patterns of Long-Term Outcome Defining PD Subtypes Based on Patterns of Long-Term Outcome

Fox (Michael J.) Foundation for Parkinson's Research

03-2008

Protocol #TRO107 Protocol #TRO107

GE Healthcare

03-2008

Novartis/Protocol #ELC200/A2401 Novartis/Protocol #ELC200/A2401

Association of American Medical Colleges

03-2008

Novartis/Protocol #ELC200/A2401 Novartis/Protocol #ELC200/A2401

Novartis Pharmaceutical Corporation

03-2008

Protocol #A to Z Protocol #A to Z

Valeant Pharmaceuticals International

01-2008

Protocol #TREND HD, AN01.01.0011, PO #412950-G Protocol #TREND HD, AN01.01.0011, PO #412950-G

University of Rochester

01-2008

PD Neuroprotection Clinical Trial: Clinical Centers PD Neuroprotection Clinical Trial: Clinical Centers

National Institute of Neurological Disorders and Stroke

10-2007

Protocol #OV-1003 Protocol #OV-1003

Ovation Pharmaceuticals, Inc.

06-2007

Prospective Huntington At Risk Observation (PHAROS) Prospective Huntington At Risk Observation (PHAROS)

University of Rochester

06-2007

PO412682-G - PHAROS PO412682-G - PHAROS

University of Rochester

06-2007

101468/228 101468/228

GlaxoSmithKline

12-2006

A Longitudinal Observational Follow-Up of the PRECEPT Study Cohort (PostCEPT) A Longitudinal Observational Follow-Up of the PRECEPT Study Cohort (PostCEPT)

Cephalon, Inc.

12-2006

A Longitudinal Observational Follow-Up of the PRECEPT Study Cohort (PostCEPT) A Longitudinal Observational Follow-Up of the PRECEPT Study Cohort (PostCEPT)

University of Rochester

11-2006

ACP-103 ACP-103

Acadia Pharmaceuticals, Inc.

10-2006

6002-INT-001 6002-INT-001

Kyowa Pharmaceutical, Inc.

09-2006

Protocol # SK&F 101468/169 Protocol # SK&F 101468/169

SmithKline Beecham

06-2006

Prospective Huntington At Risk Observation Study (PHAROS Prospective Huntington At Risk Observation Study (PHAROS

University of Rochester

04-2006

GlaxoSmithKline/Protocol #101468/205 GlaxoSmithKline/Protocol #101468/205

GlaxoSmithKline

03-2006

The Parkinson's Institute The Parkinson's Institute

Parkinson's Institute

01-2006

PROGENI PROGENI

University of Rochester

12-2005

426-404 426-404

Shire Pharmaceutical Development, Inc.

10-2005

TEVA Pharmaceuticals/Protocol #TVP 1012/135 TEVA Pharmaceuticals/Protocol #TVP 1012/135

Teva Neuroscience, Inc.

10-2005

TEVA Pharmaceuticals/Protocol #TVP 1012/135 TEVA Pharmaceuticals/Protocol #TVP 1012/135

TEVA Pharmaceutical USA

10-2005

GlaxoSmithKline/Protocol #100310 GlaxoSmithKline/Protocol #100310

GlaxoSmithKline

09-2005

Atropane-08 Atropane-08

Boston Life Sciences, Inc.

08-2005

RLS100013 RLS100013

GlaxoSmithKline

06-2005

PHAROS PHAROS

University of Rochester

06-2005

Prospective Huntington at Risk Observational Study (PHAROS) Prospective Huntington at Risk Observational Study (PHAROS)

University of Rochester

03-2005

ACADIA/PRA Int'l - Protocol #ACP-103 ACADIA/PRA Int'l - Protocol #ACP-103

Acadia Pharmaceuticals, Inc.

01-2005

PROGENI PROGENI

University of Rochester

03-2001

TVP-1012/233 TVP-1012/233

Teva Pharmaceutical Ind., Ltd.

Degrees

M.B.A.
M.D.

Publications

OpenAlex
Search Engines

Last updated on 2/5/25. See our OpenAlex FAQ for more about this data.

Search Google Scholar for Robert Hauser

OpenAlex Works Search

Presentations

Parkinson's Disease

Overview of symptoms and treatments of Parkinson's disease

Subject Areas:

Medical Sciences

Keywords:

Parkinson's Disease

Audience:

Adults

Duration:

1 hour or less

Fee:

Greater than $500

Center

USF Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence

Director	Robert Hauser
Phone	813-396-0751
Website	https://health.usf.edu/medicine/neurology/mvdisorders
Mission	Established in 1986 as a full-time speciality clinic to provide focused neurological care for individuals with Parkinson's Disease, the mission for the USF Parkinson's Disease & Movement Disorders Center is to advance knowledge and treatment for Parkinson's Disease and other Movement Disorders. Our goals are to provide superior clinical care for patients and caregivers, to teach medical students, residents, and other healthcare providers, and to expand knowledge through research. We develop and evaulate new medical and surgical treatments for Parkinson's Disease and hope one day to assist in developing a cure.

Co-Investigator Network

Theresa Zesiewicz

Professor

University of South Florida

Neurology, Morsani College Of Medicine

tzesiewi@usf.edu

Juan Sanchez-Ramos

University of South Florida

jsramos@usf.edu

Inactive Expert

Eric Pfeiffer

Professor

University of South Florida

Suncoast Gerontology

Inactive Expert

Donald Policella

Program Director, Center For Child Welfare

University of South Florida

Child and Family Studies, College Of Behavioral and Community Sciences

Inactive Expert

Deborah Burke

University of South Florida

Neurology, College Of Medicine

Inactive Expert

Kimberlea Hauser

Assistant Director

University of South Florida

College Of Medicine, College Of Medicine

Inactive Expert

Sowsan Rasheid

Associate Professor

University of South Florida

Surgery, Morsani College Of Medicine

Inactive Expert

Silvana Carr

Assistant Professor

University of South Florida

Pediatrics, Morsani College Of Medicine

Inactive Expert

He Zhang

Assistant Professor

University of South Florida

Information Systems & Decision Sciences, Muma College Of Business

Expertnet Author Network

Experts within Florida Expertnet that have co-authored works with Robert Hauser.

Inactive Expert

Kenneth Heilman

Dis Prf&Prg Dir

University of Florida

Neurology, College-Medicine

Works Co-Authored: 186

Samuel Wu

Professor & Associate Chair

University of Florida

Re-VP For Research, Uf Research

sw45@ufl.edu

Works Co-Authored: 237

Michael Okun

Adelaide Lackner Associate Professor

University of Florida

Md-Neurology-Movement Disorder, College-Medicine, Center For Movement Disorders and Neurorestoration

okun@neurology.ufl.edu

Works Co-Authored: 1203

Kelly Foote

Professor

University of Florida

Md-Neurological Surgery, College-Medicine

foote@neurosurgery.ufl.edu

Works Co-Authored: 417

Inactive Expert

Justin Sanchez

Assistant Professor

University of Florida

Md-Peds-Neurology, College-Medicine

Works Co-Authored: 134

Inactive Expert

Keith White

Professor Emeritus

University of Florida

Ls-Psychology-General, College-Liberal Arts/Sciences

Works Co-Authored: 11

Inactive Expert

Camille Swartz

Clincal Coordinator 4

University of Florida

Md-Neurology-Admin/Educ, College-Medicine

Works Co-Authored: 7

Christopher Hass

Associate Provost, Professor

University of Florida

Pv-Administration, Office Of Provost

cjhass@ufl.edu

Works Co-Authored: 256

Irene Malaty

Barbara Padgett Dein Professor Of Neurology, Director Of Parkinson Foundation Center Of Excellence and Tourette Association Of America Center For Excellence

University of Florida

Md-Neurology-Movement Disorder, College-Medicine

irene.malaty@neurology.ufl.edu

Works Co-Authored: 193

Inactive Expert

Stacy Merritt

University of Florida

Md-Neurology-Admin/Educ, College-Medicine

Works Co-Authored: 19

Nikolaus McFarland

Associate Professor Of Neurology, Wright/Falls/Simmons Professor Of Psp/Atypical Parkinsonism

University of Florida

Md-Neurology-Movement Disorder, College-Medicine

nikolaus.mcfarland@neurology.ufl.edu

Works Co-Authored: 128

Angelos Barmpoutis

Prof

University of Florida

Cota-Digital World, College Of The Arts

angelos@digitalworlds.ufl.edu

Works Co-Authored: 76

Inactive Expert

Atchar Sudhyadhom

University of Florida

Md-Neurological Surgery, College-Medicine

Works Co-Authored: 22

David Vaillancourt

Chair & Prof

University of Florida

Hh-Apk-Administration, Research / Sponsored Programs

david.e.vaillancourt@gmail.com

Works Co-Authored: 269

Inactive Expert

Adam Falchook

University of Florida

Md-Behavioral Neurology, College-Medicine

Works Co-Authored: 23

Inactive Expert

Odinachi Oguh

University of Florida

Jx-Neurology-Jacksonville, College-Medicine Jacksonville

Works Co-Authored: 13

Arch Mainous

Professor and Vice Chair Of Research, Chfm

University of Florida

Md-Chfm-Gen Administration, College-Medicine

arch.mainous@phhp.ufl.edu

Works Co-Authored: 504

Melissa Armstrong

Professor

University of Florida

Md-Neurology-Movement Disorder, College-Medicine

melissa.armstrong@neurology.ufl.edu

Works Co-Authored: 262

John Williamson

Associate Professor

University of Florida

Md-Psychiatry, College-Medicine

john.williamson@neurology.ufl.edu

Works Co-Authored: 289

Ruogu Fang

Academic Lump Sum Payment

University of Florida

Eg-Biomedical Engineering, College-Engineering

ruogu.fang@ufl.edu

Works Co-Authored: 109

Adolfo Ramirez-Zamora

Professor Of Neurology & Division Chief Movement Disorders

University of Florida

Md-Neurology-Movement Disorder, College-Medicine

aramirezzamora@ufl.edu

Works Co-Authored: 177

Stefan Prokop

Ast Prof

University of Florida

Md-Pathology-General, College-Medicine

sprokop@ufl.edu

Works Co-Authored: 92

Matthew Farrer

Professor Of Neurology (Mol. Neuroscience and Neurogenetics)

University of Florida

Md-Neurology-Movement Disorder, College-Medicine

m.farrer@ufl.edu

Works Co-Authored: 490

Inactive Expert

Jesse DeSimone

Ast Sctst

University of Florida

Hh-Apk-Administration, College-Hlth/Human Performance

Works Co-Authored: 16

Inactive Expert

Michael Gold

University of South Florida

Neurology

Works Co-Authored: 3

Inactive Expert

Archie Silver

University of South Florida

Psychiatry and Behavioral Medicine

Works Co-Authored: 26

Inactive Expert

Tanja Zigova

University of South Florida

College Of Medicine

Works Co-Authored: 24

Theresa Zesiewicz

Professor

University of South Florida

Neurology, Morsani College Of Medicine

tzesiewi@usf.edu

Works Co-Authored: 151

Juan Sanchez-Ramos

University of South Florida

jsramos@usf.edu

Works Co-Authored: 225

Inactive Expert

Kenneth Zuckerman

University of South Florida

Works Co-Authored: 5

Inactive Expert

Alexander Rosemurgy

Professor

University of South Florida

Dept Of Surgery

Works Co-Authored: 41

Douglas Holt

Professor

University of South Florida

Internal Medicine, Morsani College Of Medicine

daholt@usf.edu

Works Co-Authored: 28

Alison Willing

Professor

University of South Florida

Neurosurgery and Brain Repair, Morsani College Of Medicine

awilling@hsc.usf.edu

Works Co-Authored: 159

Thomas Freeman

Professor

University of South Florida

Department Of Neurosurgery and Brain Repair

tfreeman@health.usf.edu

Works Co-Authored: 58

Paul Sanberg

Sr VP Usf & Dist Professor

University of South Florida

Usf Research & Innovation, Usf Research & Innovation

psanberg@usf.edu

Works Co-Authored: 529

Inactive Expert

Cynthia Cimino

Associate Professor

University of South Florida

Psychology, College Of Arts and Sciences

Works Co-Authored: 12

Cesario Borlongan

Distinguished Health Professor

University of South Florida

Neurosciences Center For Aging, Morsani College Of Medicine

cborlong@usf.edu

Works Co-Authored: 199

Inactive Expert

Skai Schwartz

Assoc Professor

University of South Florida

Public Health Interdisciplinary Research and Education, College Of Public Health

Works Co-Authored: 15

Inactive Expert

Ross Andel

Director & Professor

University of South Florida

School Of Aging Studies, College Of Behavioral and Community Sciences

Works Co-Authored: 113

Jason Salemi

Interim Chair & Professor

University of South Florida

Public Health Interdisciplinary Research and Education, College Of Public Health

jsalemi@usf.edu

Works Co-Authored: 285

Sagarika Nallu

Chief, Division Of Neurology

University of South Florida

Pediatrics, Morsani College Of Medicine

snallu@usf.edu

Works Co-Authored: 13

Yarema Bezchlibnyk

Assistant Professor

University of South Florida

Neurosurgery, Morsani College Of Medicine

yaremab@usf.edu

Works Co-Authored: 64

Stephen Aradi

Assistant Professor

University of South Florida

Neurology, Morsani College Of Medicine

saradi@usf.edu

Works Co-Authored: 15

Carlos Singer

University of Miami

Neurology, Medical

csinger@miami.edu

Works Co-Authored: 270

Joanne Wuu

University of Miami

Neurology, Medical

jwuu@miami.edu

Works Co-Authored: 154

Websites

OpenAlex Works Search

Search Google Scholar for Robert Hauser

Contact Information

rhauser@health.usf.edu

(813) 396-0751

University of South Florida -Byrd Institute
4001 E. Fletcher Avenue
Suite 620
Tampa, FL 33613

Profile QR code

What is this?

Robert Hauser

Medical Director

USF PARKINSON'S DISEASE AND MOVEMENT DISORDERS | MORSANI COLLEGE OF MEDICINE

Research Terms & Keywords

Research Projects

Degrees

Publications

Presentations

Center

Co-Investigator Network

Expertnet Author Network

Websites

Contact Information

About

Discover

Connect

Keyword Search

Browse by STEM